.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

AGENERASE Drug Profile

« Back to Dashboard
Agenerase is a drug marketed by Glaxosmithkline and is included in two NDAs. There is one patent protecting this drug.

This drug has fifty patent family members in forty countries.

The generic ingredient in AGENERASE is amprenavir. There are five drug master file entries for this compound. Additional details are available on the amprenavir profile page.

Summary for Tradename: AGENERASE

Patents:1
Applicants:1
NDAs:2

Clinical Trials for: AGENERASE

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
AGENERASE
amprenavir
CAPSULE;ORAL021007-001Apr 15, 1999DISCNNo6,730,679<disabled>Y <disabled>
Glaxosmithkline
AGENERASE
amprenavir
CAPSULE;ORAL021007-002Apr 15, 1999DISCNNo6,730,679<disabled>Y <disabled>
Glaxosmithkline
AGENERASE
amprenavir
SOLUTION;ORAL021039-001Apr 15, 1999DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: AGENERASE

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
AGENERASE
amprenavir
SOLUTION;ORAL021039-001Apr 15, 19995,646,180<disabled>
Glaxosmithkline
AGENERASE
amprenavir
SOLUTION;ORAL021039-001Apr 15, 19995,723,490<disabled>
Glaxosmithkline
AGENERASE
amprenavir
CAPSULE;ORAL021007-001Apr 15, 19995,585,397<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: AGENERASE

Country Document Number Estimated Expiration
Australia2159197<disabled in preview>
Norway317639<disabled in preview>
European Patent Office0906107<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: AGENERASE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008006,C0933372Lithuania<disabled>PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
/2008Austria<disabled>PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713
0933372/01Switzerland<disabled>PRODUCT NAME: FOSAMPRENAVIR; REGISTRATION NUMBER/DATE: SWISSMEDIC 56706 17.03.2005
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc